The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients

Background: Bevacizumab combined with chemotherapy is still one of the standard options for treatment of advanced non-small cell lung cancer (NSCLC) patients without driver mutations. Serum inflammatory factors, representing the systemic immune status, are shown to have complicated relationships wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Butuo, Wang, Shijiang, Li, Cheng, Guo, Meiying, Xu, Yiyue, Sun, Xindong, Yu, Jinming, Wang, Linlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775608/
https://www.ncbi.nlm.nih.gov/pubmed/31602260
http://dx.doi.org/10.7150/jca.30478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775608/
https://www.ncbi.nlm.nih.gov/pubmed/31602260
http://dx.doi.org/10.7150/jca.30478

Ejemplares similares